New trial results reveal that combining pembrolizumab and enfortumab vedotin significantly enhances survival rates in muscle-invasive bladder cancer patients.
Christof Vulsteke, MD, PhD
Advertisement
Articles by Christof Vulsteke, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
The Targeted Pulse: FDA Approvals, Trial Updates, and ASH 2025 Previews
3
Odronextamab Plus CHOP Shows Promise in Early Phase 3 Data for Untreated DLBCL
4
Lisaftoclax Monotherapy Achieves Significant Responses and PFS in R/R CLL/SLL
5
